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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.020Triple-negative breast cancer (TNBC) is an aggressive subtype deﬁned by the lack of estrogen receptor,
progesterone receptor, and human epidermal growth factor receptor 2 expression. Expression of miR-21,
an oncomiR, is frequently altered and may be distinctly expressed in the tumor stroma. Because tumor
lesions are a complex mixture of cell types, we hypothesized that analysis of miR-21 expression at single-
cell resolution could provide more accurate information to assess disease recurrence risk and BC-related
death. We implemented a fully automated, tissue slideebased assay to detect miR-21 expression in 988
patients with BC. The miR-21High group exhibited shorter recurrence-free survival [hazard ratio
(HR), 1.71; P< 0.001] and BC-speciﬁc survival (HR, 1.96; P< 0.001) in multivariate regression analyses.
When tumor compartment and levels of miR-21 expression were considered, signiﬁcant associations with
poor clinical outcome were detected exclusively in tumor epithelia from estrogen receptore and/or
progesterone receptorepositive human epidermal growth factor receptor 2enegative cases [recurrence-
free survival: HR, 3.67 (PZ 0.006); BC-speciﬁc survival: HR, 5.13 (PZ 0.002)] and in tumor stroma from
TNBC cases [recurrence-free survival: HR, 2.59 (PZ 0.013); BC-speciﬁc survival: HR, 3.37 (PZ 0.003)].
These ﬁndings suggest that the context of altered miR-21 expression provides clinically relevant in-
formation. Importantly, miR-21 expression was predominantly up-regulated and potentially prognostic
in the tumor stroma of TNBC. (Am J Pathol 2014, 184: 3217e3225; http://dx.doi.org/10.1016/
j.ajpath.2014.08.020)Supported by National Cancer Institute grants R03 CA141564 and R21
CA141017 (L.F.S.), National Center for Research Resources grant R21
RR024411 (W.A.W.), Van Andel Research Institute research funds
(L.F.S.), a Hitchcock Foundation pilot grant (L.F.S.), and generous dona-
tions to the VAI Purple Community fund to support breast cancer research
(L.F.S).
Disclosures: None declared.Breast cancer (BC) is a highly heterogeneous disease con-
sisting of several molecular subtypes that correlate with
clinical outcome. Expression levels of estrogen receptor
(ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2) are used to deﬁne the major
subtypes, with ERþ tumors having a signiﬁcantly better
prognosis than ER tumors.1,2 Patients with BC have
beneﬁted from recent advances in molecular diagnostic as-
says. For ERþ cases, assays that are gene expression based
(ie, OncoType Dx, Mammaprint, and PAM50) and tissue
slide based [eg, immunohistochemistry (IHC) 4 and Mam-
mostrat] can reﬁne risk assessment for recurrence and iden-
tify patients who may beneﬁt from intensive adjuvant
treatments in addition to hormonal therapy.1e4 For HER2þ
cases, overexpression of HER2 is a predictive biomarker for
response to targeted treatment against HER2 signaling.5stigative Pathology.
.However, for ER cases, there are no salient prognostic
markers.6 This is particularly relevant for triple-negative BC
(TNBC), which accounts for 15% to 20% of BC cases and is
deﬁned by the lack of ER, PR, and HER2 expression.7,8
TNBCs are associated with shorter recurrence free survival
(RFS) and BC-speciﬁc survival (CSS) relative to other major
BC subtypes. TNBC is still a heterogeneous group of dis-
eases, and gene expression proﬁling methods have suggested
MacKenzie et althe existence of distinct subgroups.9,10 Currently, TNBC is
treated with different cytotoxic combination chemotherapy;
complete response to neoadjuvant chemotherapy, depending
on speciﬁc treatment regimens, varies widely, between 8%
and 83%.9 Thus, predictive biomarkers for therapeutic
response prediction and novel therapeutic targets that address
distinct biological features of TNBC subgroups are needed
for these patients.7,8
Interactions between tumor epithelia (cancer cells) and the
tumor microenvironment (TME) play a major role in BC
progression. The TME is composed of a complex network of
stromal cells, immune cells, extracellular matrix, and cyto-
kines/chemokines. Stromal gene expression signatures have
been identiﬁed that predict outcome and treatment response in
BC.11,12 The tumor/stroma ratio of patients with TNBC is
particularly predictive of relapse.13 Despite the overwhelming
data on the inﬂuence of the TME, cancer diagnostics and
therapeutics are directed primarily at targeting the tumor
epithelia.
miRNAs are a class of short, noncoding, regulatory RNAs
that modulate gene expression in important developmental,
physiological, and pathological processes.14 A single miRNA
can down-regulate the expression of hundreds of target genes
by binding to a partially complementary site in the 30-un-
translated region of their cognate mRNAs. The clinical im-
plications of miRNA biological features are generating great
interest in the areas of cancer research and cancer medi-
cine.15e19 miRNA-based diagnostics is an emerging area of
novel prognostic and predictive indicators, and somemiRNAs
have provided leads for the development of novel targeted
therapies.17,18,20 Quantitative real-time RT-PCR expression
analysis of miRNAs in formalin-ﬁxed tissue specimens are
now offered commercially as ancillary tests for identifying the
organ site of cancers of unknown primary, for performing
differential diagnosis of pancreatic cancer, and for obtaining
subtype classiﬁcation of lung and renal cell cancers.21
Altered expression ofmiR-21 has been associatedwith poor
disease outcome in various cancer types.22e28 Both in vitro
and in vivo work has demonstrated the signiﬁcant role that
miR-21 plays in tumorigenesis and the potential of miR-21 as
a therapeutic target.29,30 miR-21 also exerts ﬁbrogenic func-
tions, promoting ﬁbrosis in mouse models of renal and cardiac
injuryeinduced failure as well as in in vitro co-culture studies
of colon and pancreatic cancer cell lines.31e34 We and others
have demonstrated that miRNA expression in the tumor
epithelia versus the stroma can result in distinct clinical
implications.20,35e39 It is not clear whether miR-21 exerts its
tumorigenic functions in BC primarily within cancer cells or in
other cellular elements of the TME. Research using in situ
hybridization (ISH) has suggested that miR-21 expression is
predominantly up-regulated in the tumor stroma.35,40e42 The
few BC cases in these studies precluded prognostic evaluation
of this marker.
Herein, we conducted an adequately powered ISH-based
study on 901 BC cases to test the hypothesis that both the levels
and tumor compartment of miR-21 expression in primary BC3218tumor tissues are informative for predicting RFS and CSS. We
observed that miR-21 expression was signiﬁcantly associated
with clinical outcome in different BC subtypes on the basis of
ER-PR/HER2 status. This association was tumor compartment
speciﬁc and was inﬂuenced by the intrinsic biological features
of major BC subtypes. Speciﬁcally, high expression of miR-21
in the tumor epithelia in ERþ and/or PRþHER2 cases was
associated with poor clinical outcome, and high expression of
miR-21 in tumor stroma was associated with a much poorer
clinical outcome in TNBC.
Materials and Methods
Patient Cohort
Tissuemicroarrays (TMAs) representing tissue cores from 988
female patients diagnosed with nonmetastatic invasive BC
between 1985 and 1997 (stage I, sets 9 to 13; and stage II, sets
14 to 17) were acquired from the National Cancer Institute
(NCI) Cancer Diagnosis Program (CDP; http://cdp.nci.nih.
gov/breast/prognostic_cs.html, last accessed September 19,
2014). This NCI CDP 2008 Series Prognostic TMAs include
590 stage I and 398 stage II cases. The Institutional Review
Board (Dartmouth College Committee for the Protection of
Human Subjects) approved a waiver for the entire consent
process and use of a consent form (Committee for Protection
of Human Subjects number 22042).
ISH and IHC
A ﬂuorescence-based ISH/IHC assay was conducted as pre-
viously described,35 with slight modiﬁcations, on a Leica
BOND-MAX automated staining station (Leica Biosystems,
Buffalo Grove, IL) in the Dartmouth Pathology Translational
Research Laboratory, a College of American Patholo-
gists’eaccredited Clinical Laboratory Improvement Amend-
mentsecertiﬁed facility. miR-21 staining was calibrated by
adjusting probe concentration and ﬂuorescent substrate
incorporation time so that no signal was detectable in adjacent
normal tissue of BC tumor lesions. Brieﬂy, double-tagged
miR-21 (FAM2X) and snRNA U6 (biotin2X) locked nucleic
acidemodiﬁed DNA probes at 50 nmol/L each were hybrid-
ized to tissue slides for 75minutes at 45C. Expression ofmiR-
21, U6, and cytokeratin (CK) 19was assessedwith appropriate
antibody combinations, followed by sequential rounds of
HRP-mediated deposition of appropriate ﬂuorochrome-
conjugated tyramine substrates for 20 minutes. Fluorescent
images were captured with an EXi Aqua QImaging camera
(QImaging, Surrey, BC, Canada) mounted on a BX51 mi-
croscope (Olympus, Center Valley, PA). Image-Pro Plus
software version 7.0 (Media Cybernetics, Rockville, MD) was
used for histogram-based image segmentation analysis.
Eighty-seven cores were excluded because of insufﬁcient
representation of tumor lesions and/or lack of stain for all
markers. miR-21 signal intensity was scored in two locations,
tumor epithelium and stroma, on a scale from 0 (noajp.amjpathol.org - The American Journal of Pathology
miR-21 for Assessment in Breast Cancerexpression) to 3 (high expression). For assessing correlations
with clinicopathological factors, sample tissue cores were
considered low (0 or 1) or high (2 or 3) for each location
(Supplemental Table S1). This scoring system was indepen-
dently validated by multiviewer (L.F.S. and W.A.W.) and
computer-assisted image segmentation analyses on digital
images captured from a representative subset of 399 cases
(Supplemental Figure S1).
Statistical Analysis
We followed the REMARK guidelines for reporting of prog-
nostic markers43,44 and the NCI CDP’s recommendations for
data set analysis (http://cdp.nci.nih.gov/breast/prognostic_dm.
html, last accessed September 19, 2014). These TMAs have a
robust statistical design to detect associations between tumor
markers and clinical outcome in nonmetastatic BC cases.
TMA sample sizes were determined by NCI statisticians to
detect a hazard ratio (HR) of 2.0 with 80% or greater power.
Associations between miR-21 expression and clinicopatho-
logical factors were assessed by t-test, c2 test, or Fischer’s
exact test (Supplemental Appendix S1). Kaplan-Meier curvesTable 1 Patient Characteristics and miR-21 Expression Data
Characteristic Condition
miR-21 compartment Tumor epithelia expression
Tumor stroma expression
No expression
miR-21 score High
Low
Age (years) <55
>55
Tumor size (cm) <2
>2
LN status N0
N1
Grade 1
2
3
Stage I
II
ER status Negative
Positive
Data not available
PR status Negative
Positive
Data not available
HER status Negative
Positive
Data not available
ER/PR/HER2 subtype ERþ and/or PRþHER2e
(any ER or PR) HER2þ
ERePReHER2e
Data not available
Data are given as number and percentage of cases in each category for miR-21
prognostic factors. Additional patient characteristics are provided in Supplement
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lym
PR, progesterone receptor.
The American Journal of Pathology - ajp.amjpathol.org(which estimate survival if death from other causes were
eliminated as a possibility) of RFS and CSS were constructed.
RFS was deﬁned as the time to any documented recurrence
event or time of death with evidence of BC in the absence of an
earlier documented recurrence event; CSS was deﬁned as time
before death with evidence of BC. Kaplan-Meier curves were
compared using the log-rank test. Cause-speciﬁc HRs, sub-
distribution HRs, and their 95% CIs were derived using the
Cox proportional hazards model. Unless otherwise noted, re-
ported HRs correspond to results from the multivariate Cox
proportional hazards regressionmodel, adjusted for age, tumor
size, lymph node involvement, and grade. All statistical ana-
lyses were performed using the R software package (http://
www.r-project.org).
Results
miR-21 Is Predominantly Expressed in the Tumor
Stroma in Breast Cancer
To investigate the prognostic value of tumor compartment
and levels of miR-21 expression in BC, we determined then % of Total % of Available
45 5.00 5.00
341 37.80 37.80
515 57.20 57.20
207 23.00 23.00
694 77.00 77.00
331 36.70 36.70
570 63.30 63.30
646 71.70 71.70
255 28.30 28.30
642 71.30 71.30
259 28.70 28.70
249 27.60 27.60
412 45.70 45.70
240 26.60 26.60
520 57.60 57.60
381 42.40 42.40
182 20.20 23.82
582 64.60 76.18
137 15.20 NA
233 25.90 30.46
532 59.00 69.54
136 15.10 NA
658 73.00 85.34
113 12.50 14.66
130 14.40 NA
549 60.93 72.14
107 11.88 14.06
105 11.65 13.80
140 15.54 NA
expression data and patient characteristics currently used in the clinic as
al Table S1.
ph node; NA, not applicable because data are missing for these categories;
3219
MacKenzie et alexpression of miR-21, snRNA U6, and CK19 protein on
tissue cores represented in the NCI CDP Prognotic TMAs,
using a fully automated ﬂuorescence-based multiplex ISH/
IHC assay.35 Expression of snRNA U6 was used to assess
RNA quality, and expression of CK19 was used to identify
the tumor epithelia in each tissue core. In total, 901 cases
were included in the analysis. Molecular and clinicopatho-
logical characteristics are summarized in Table 1, and the
complete data set with clinical outcomes is provided in
Supplemental Table S1.
miR-21 expression was detected in 386 (42.8%) of the 901
cases. miR-21 was predominantly or exclusively expressed
within the tumor stroma compartment (CK19e cells) in most
cases (88.3%), whereas it was conﬁned to the tumor epithelia
compartment (CK19þ cells) in a few cases (11.7%). We
previously determined by microarray and Northern blot an-
alyses that miR-21 was expressed at high levels in the MCF7
BC cell line and was not expressed in the MCF10A BC
line.40 Therefore, we used cores of these BC cell lines rep-
resented in TMA slides as a reference for scoring miR-21
expression levels (Figure 1). Cases were reviewed under
ﬂuorescent microscopy and assigned a score of low (694
cases) or high (207 cases) on the basis of signal intensity.
This miR-21 score provided a threshold that further separatedFigure 1 Patterns, quantiﬁcation, and scoring of miR-21 expression in breast
miR-21, snRNA U6, and CK19 in BC cell lines (A) and tissue cores (B). miR-21 he
analysis; the background signal was set on the basis of exposed slide areas (eg, tis
intensity (black) as onefold (blue), twofold (cyan), threefold (orange), and fourfold
categorized low and high miR-21 expression, respectively. C: Summary of miR-21
on the basis of ER/PR/HER2 status in entire patient cohort. Original magniﬁcatio
3220nonexpressing and low-expressing cases from those with
higher miR-21 expression.
miR-21 Score Is an Independent Risk Factor Associated
with Poor Disease Outcome
The miR-21High group had an increased risk for shorter RFS
(Supplemental Tables S2 and S3) and CSS (Tables 2 and 3) at
5 years after diagnosis and during the overall follow-up period
(median, 10.33 years). Stratiﬁcation of cases by standard
clinicopathological characteristics indicated that the miR-21
score was an independent risk factor associated with poor
disease outcome (Tables 2 and 3 and Supplemental Tables S4
and S5). Notably, the miR-21High grade 2 subgroup had a
much higher risk relative to the miR-21Low grade 2 subgroup
for shorter RFS (5 years: HR, 3.85; P < 0.001) and CSS
(5 years; HR, 5.51; P < 0.001) and a similar risk as the
miR-21Low grade 3 subgroup (Supplemental Table S4).
Tumor CompartmenteSpeciﬁc Expression of miR-21
Deﬁnes Risk in Distinct Molecular Subtypes
To assess the contribution of tumor compartment of miR-21
expression to the risk associated with disease outcome, thecancer lesions. A and B: Representative images of multicolor detection of
at map images were generated using histogram-based image segmentation
sue holes). Other categories were deﬁned relative to the highest background
or more (red) over background. Cases with a score of 1 to 2 and 3 to 4 were
expression levels, tumor compartment of expression, and molecular subtype
n, 200 (A and B). Ca, tumor epithelia; Stroma, tumor stroma.
ajp.amjpathol.org - The American Journal of Pathology
Table 2 CSS Risk Associated with miR-21 Expression for Disease Outcome 5 Years after Diagnosis
Group Variable
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
All cases (n Z 901) miR-21High/Low 2.69 1.65e4.39 <0.001 2.31 1.41e3.79 <0.001
miR-21HiCancer/Low 3.86 1.35e11.03 0.010 3.04 1.05e8.86 0.037
miR-21HiStroma/Low 2.57 1.54e4.28 <0.001 2.22 1.32e3.73 0.002
Grade 1/2 0.40 0.132e1.235 0.105 0.48 0.16e1.48 0.195
Grade 3/2 5.53 3.10e9.85 <0.001 4.51 2.50e8.13 <0.001
Stage II/I 4.42 2.52e7.74 <0.001 1.04 0.36e3.05 0.937
ERþ and/or PRþHER2 (n Z 549) miR-21High/Low 3.15 1.46e6.81 0.003 2.57 1.18e5.61 0.016
miR-21HiCancer/Low 9.46 2.65e33.80 <0.001 7.05 1.75e28.44 0.005
miR-21HiStroma/Low 2.62 1.15e6.01 0.020 2.15 0.93e4.99 0.069
ERPR HER2 (n Z 105) miR-21High/Low 2.50 1.03e6.08 0.039 2.82 1.10e7.26 0.028
miR-21HiCancer/Low NA NA NA NA NA NA
miR-21HiStroma/Low 2.84 1.17e6.90 0.019 3.09 1.20e7.98 0.017
Data are given as HRs and their 95% CIs for miR-21 expression and standard clinical indicators using Cox proportional hazard models. The following variables
were adjusted for in multivariate analyses: age, tumor size, grade, and lymph node involvement. Risks associated with miR-21High score are reported as a whole
group (miR-21High) and as subgroups (miR-21HiCancer and miR-21HiStroma) divided by tumor compartment of expression.
NA, not applicable because not enough data entries for this category to perform analysis.
miR-21 for Assessment in Breast CancermiR-21High group was subdivided into a miR-21HiCancer
subgroup of 20 cases, which included only cases with tumor
epitheliaespeciﬁc expression, and a miR-21HiStroma group
of 187 cases with predominant expression in the tumor stroma.
The miR-21HiCancer subgroup had a higher risk for shorter
RFS and CSS (Tables 2 and 3 and Supplemental Tables S4 and
S5) than the miR-21HiStroma subgroup relative to the miR-
21Low group. Because the ER/PR/HER2 status of breast can-
cer tumors drives their biological features and evolution,1,2,6,45
we determined if ER/PR/HER2 status inﬂuenced the tumor
compartmentespeciﬁc effects of altered miR-21 expression.
When cases were stratiﬁed by the status of individual re-
ceptors, poor clinical outcome for the miR-21HiCancer sub-
group was only statistically signiﬁcant in ERþ cases or in PRþ
cases, and for the miR-21HiStroma subgroup, in ER cases or
PR cases (Supplemental Tables S4 and S5). In addition, poorTable 3 CSS Risk Associated with miR-21 Expression for Overall Disea
Group Variable
Univariat
HR
All cases (n Z 901) miR-21High/Low 1.94
miR-21HiCancer/Low 2.61
miR-21HiStroma/Low 1.88
Grade 1/2 0.49
Grade 3/2 2.57
Stage II/I 3.15
ERþ and/or PRþHER2 (n Z 549) miR-21High/Low 1.70
miR-21HiCancer/Low 4.25
miR-21HiStroma/Low 1.53
ERPR HER2 (n Z 105) miR-21High/Low 2.62
miR-21HiCancer/Low 2.25
miR-21HiStroma/Low 2.66
Data are given as HRs and their 95% CIs for miR-21 expression and standard clin
were adjusted for in multivariate analyses: age, tumor size, grade, and lymph node
group (miR-21High) and as subgroups (miR-21HiCancer and miR-21HiStroma) divided
The American Journal of Pathology - ajp.amjpathol.orgclinical outcome associated with the miR-21HiCancer and miR-
21HiStroma subgroups was statistically signiﬁcant only for
HER2 cases (Figures 2 and 3 and Supplemental Tables S4
and S5). When cases were stratiﬁed by the combined status
of ER/PR/HER2 as molecular surrogate of major gene
expression subtypes,45 poor clinical outcome associated with
themiR-21HiCancer subgroup in ERþ and/or PRþHER2 cases
(5-year CSS: HR, 7.05; P Z 0.005). The miR-21HiStroma
subgroup (Figures 2 and 3 and Tables 2 and 3) was associated
with poor outcome in ERPRHER2 cases (5-year CSS:
HR, 3.09; PZ 0.017).
Discussion
miRNA diagnostics is an emerging area of novel prognostic
and predictive indicators for BC. Tissue slideebased assaysse Outcome
e Multivariate
95% CI P value HR 95% CI P value
1.38e2.75 <0.001 1.96 1.38e2.78 <0.001
1.13e6.05 0.023 2.74 1.17e6.39 0.018
1.31e2.70 <0.001 1.88 1.31e2.72 <0.001
0.29e0.84 0.007 0.56 0.33e0.96 0.032
1.81e3.66 <0.001 2.16 1.51e3.10 <0.001
2.23e4.43 <0.001 0.97 0.48e1.94 0.925
1.05e2.75 0.028 1.81 1.11e2.95 0.016
1.51e11.98 0.005 5.13 1.75e15.07 0.002
0.91e2.55 0.100 1.61 0.96e2.70 0.068
1.24e5.55 0.010 3.29 1.47e7.37 0.003
0.29e17.56 0.431 2.71 0.32e22.71 0.338
1.23e5.77 0.011 3.37 1.45e7.81 0.004
ical indicators using Cox proportional hazard models. The following variables
involvement. Risks associated with miR-21High score are reported as a whole
by tumor compartment of expression.
3221
Figure 2 Kaplan-Meier plots of disease recurrence on the basis of miR-21 expression. Kaplan-Meier survival curves for breast cancerespeciﬁc recurrence
were plotted by miR-21 category for all cases or major subtypes on the basis of ER/PR/HER2 status. Curves were also plotted by tumor compartment (miR-
21HiCancer, miR-21HiStroma, and miR-21Low).
MacKenzie et alare routine procedures in clinical laboratories to diagnose,
prognosticate, and guide treatment selection. To facilitate
clinical integration of ancillary miRNA detection assays, we
implemented a tissue slideebased fully automated staining
assay in a Clinical Laboratory Improvement Amend-
mentsecertiﬁed environment. Herein, we used this multiplex
ﬂuorescent assay to determine molecular and cellular char-
acteristics of BC tumors by measuring the tumor compart-
ment and levels of miR-21 expression. In this biomarker
discovery study, we found that contextual expression of miR-
21 provided clinically relevant information.
We determined altered expression of miR-21 at single-cell
resolution and extracted this contextual information from theFigure 3 Kaplan-Meier plots for disease outcome on the basis of miR-21 expr
plotted by miR-21 category for all cases or major subtypes on the basis of ER/PR/H
miR-21HiStroma, and miR-21Low).
3222tumor epithelia and stroma (Figure 1). This large retrospective
study in a patient cohort of 901 early-stage BC cases indicated
that both expression levels and compartment-speciﬁc expres-
sion of miR-21 contained prognostic information. This infor-
mation was independent of standard clinicopathological
characteristics (Tables 2 and 3), including tumor grade, which is
indicative of the differentiation status and proliferative rate of
cancer cells. Tumor grade is an important factor in prognostic
tools, such as the Nottingham Prognostic Index and Adjuvant!
Online.46 The prognostic value of grade is limited in ER cases
(HER2-overexpressing and TNBC subtypes) because these
tumors frequently have a high grade (grades 2/3).46 Our results
suggest that a combination of miR-21 score (tumor stromaession. Kaplan-Meier survival curves for breast cancerespeciﬁc deaths were
ER2 status. Curves were also plotted by tumor compartment (miR-21HiCancer,
ajp.amjpathol.org - The American Journal of Pathology
miR-21 for Assessment in Breast Cancercharacteristic) and grade (tumor epithelia characteristic) may be
useful for identifying tumors having more aggressive features.
By using RNA extracted from whole tissue biopsy speci-
mens, altered expression of miR-21 has been frequently
observed in BC and other cancer types.20,47 Functional studies
have uncovered oncogenic properties of miR-21 in cancer cell
lines and in mouse models of cancer.16,48 Implicit in these
ﬁndings is the idea that miR-21emediated regulation is
conﬁned to cancer cellespeciﬁc processes. We identiﬁed a
small subgroup of cases with high miR-21 expression exclu-
sively within the tumor epithelia (Figure 1) that were associ-
ated with poor clinical outcome (Figures 2 and 3). However,
our results indicate that most BC tumors up-regulate miR-21
expression in the tumor stroma (Figure 1). Thus, miR-
21emediated regulation of biological processes in the reactive
tumor stroma is likely a more frequent mechanism by which
miR-21 affects BC tumor biological features. The fact that
high levels of expression in the tumor stroma were associated
with poor disease outcome in ERPRHER2/TNBC cases
(Figures 2 and 3) suggests that the intrinsic biological features
of different subtypes contextualizes the effect and inﬂuence of
miR-21 activity. Consequently, miR-21 expression levels,
tumor compartment of miR-21 expression, and molecular
characteristics (eg, ER/PR/HER2 status) appear to contribute
to the biological effects of miR-21 and its value as a prognostic
indicator and potential therapeutic target in BC.
The association between miR-21 expression and TNBC
subtype is highly relevant. There are currently a few speciﬁc
prognostic markers and no effective targeted therapies for
TNBC.7e10 Seminal studies using gene expression proﬁling
identiﬁed an aggressive basal-like subtype, which was highly
enriched for TNBC cases, on the basis of intrinsic cancer cell
characteristics.49,50 More recently, systems biology and inte-
grative pathway analysis approaches have deﬁned gene
expression signatures that classify TNBC into four to six
subgroups.2,51e53 Stromal expression of mesenchymal cells
and inﬁltrating immune cells are main attributes of some of
these subgroups. It will be important to determine whether
stromal expression of miR-21 correlates with one of more of
these TNBC subgroups with tumorigenic stromal features or is
an independent risk factor.
We previously showed that miR-21 was expressed in
tumor stromal cells that also expressed smooth muscle actin
and vimentin in BC tissues.35 Although we did not costain
with these (myo)ﬁbroblast markers in this study, the
morphological features of miR-21eexpressing cells were
consistent with those of tumor-associated ﬁbroblasts.
miR-21 expression in tumor stromal ﬁbroblast-like cells has
been recently associated with poor clinical outcome in colon
and pancreatic cancers.31,39,54 Moreover, in vitro co-culture
studies of cancer cell lines and ﬁbroblasts (either from estab-
lished cell lines or freshly derived from patients) indicate that
miR-21 inﬂuences ﬁbrogenic processes that enhance cancer
cell aggressiveness and invasion.31,32 In the colon cancer co-
culture model, the reversion-inducing cysteine-rich protein
with kazal motifs, a negative regulator of prometastatic matrixThe American Journal of Pathology - ajp.amjpathol.orgmetalloprotease 2, was identiﬁed as a key target of miR-21.32
In cardiac and/or renal mouse models of injury-induced
ﬁbrosis, key targets of miR-21 were identiﬁed as sprouty ho-
molog 1/2 of Drosophila gene, programmed cell death 4,
peroxisome proliferatoreactivated receptor a, and phospha-
tase and tensin homolog.33,34 miR-21 has also been shown to
regulate these same target mRNAs in cancer cell lines,55
suggesting that there is at least some overlap of miR-21 ac-
tivity in different cell types and diseases. This knowledge
could be exploited to implement tumor compartmentespeciﬁc
antiemiR-21ebased therapies in BC, especially in TNBC
cases for which effective targeted therapies are still lacking.7
Computer-assisted morphological analyses identiﬁed stro-
mal features that correlated with poor outcome in BC.56e58 It
is an intriguing possibility that altered miR-21 expression
may cause some of these morphological manifestations. We
determined contextual miR-21 expression and generated a
miR-21 score on the basis of tissue core stains (Figure 1).
Although we discarded tissue cores that did not contain tumor
lesions, it is possible that not all cores that we analyzed pro-
vided an optimal sampling of the entire tumor. Patients in this
study cohort were diagnosed with BC between 1985 and 1997
and were treated in different health care centers. Treatments
varied: 47.4% of patients received only local therapy, and
52.6% of patients also received adjuvant treatment (hormone
therapy and/or chemotherapy) (Supplemental Table S1).
Adjuvant treatments did not match current protocols, namely,
use of third-generation aromatase inhibitors (eg, exemestane
and anastrozole) for ERþ cases, antieHER2-targeted therapies
(eg, herceptin) for HER2-overexpressing cases, and modiﬁ-
cations in chemotherapy combinations and modalities for
speciﬁc patient subtypes and subgroups. Thus, one should be
cautious when interpreting the prognostic value of altered
miR-21 expression due to diverse treatment histories. An
important ﬁrst step to address these caveats and to pursue
clinical implementation of a tissue slideebased miR-21
detection assay will be to validate these ﬁndings in whole-
tissue specimens via multi-institutional clinical studies.
Future studies are also needed to investigate whether miR-21
expression could serve as a predictive indicator of treatment
response in clinical trials evaluating speciﬁc treatments. Such
studies would reinforce the concept that miR-21 activity in the
TME is biologically relevant in BC.
In conclusion, this study provides both a promising
miRNA prognostic biomarker and a robust method to bring
tissue slideebased miRNA detection assays closer to
routine clinical practice. If these ﬁndings are supported
and validated by independent clinical studies, the tumor
compartment and level of miR-21 expression could become
useful ancillary indicators for risk stratiﬁcation in speciﬁc
BC subtypes or their subgroups.
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